Skip to main content
. 2023 Sep 4;13:14548. doi: 10.1038/s41598-023-41662-9

Table 4.

Logistic regression analyses of autonomic symptoms of patients with PD.

OR 95% CI p value
Gastrointestinal symptom
 Age 1.04 1.02 to 1.06 0.001
Hoehn and Yahr stage
 Stage 1 Ref
 Stage 1.5 0.73 0.35 to 1.52 0.39
 Stage 2 1.35 0.85 to 2.13 0.20
 Stage 2.5 3.95 0.70 to 74.9 0.20
 Stage 3 0.14 0.04 to 0.48 0.002
  MDS-UPDRS I score 1.20 1.10 to 1.31  < 0.001
  MDS-UPDRS II score 1.16 1.09 to 1.24  < 0.001
  pRBD
   No Ref
   Yes 2.13 1.26–3.70 0.006
Urinary symptom
 Age 1.05 1.01–1.08 0.006
 MDS-UPDRS I score 1.30 1.14–1.52 0.0003
 MDS-UPDRS II score 1.17 1.08–1.28 0.0004
 Depression
  No Ref
  Yes 0.36 0.18–0.71 0.0003
Cardiovascular symptom
 MDS-UPDRS I score 1.11 1.05–1.17 0.0002
 MDS-UPDRS II score 1.07 1.02–1.11 0.002
 pRBD
  No Ref
  Yes 1.45 0.99–2.13 0.056
 Subtype
  PIGD Ref
  TD 1.64 1.05–2.58 0.03
  Indeterminate 2.27 1.29–4.02 0.004
Thermoregulatory symptom
 MDS-UPDRS I score 1.16 1.09–1.22  < 0.001
 MDS-UPDRS III score 0.97 0.95–0.99 0.01
 MDS-UPDRS IV score 1.32 1.12–1.57 0.001
 Subtype
  TD Ref
  PIGD 2.70 1.77–4.13  < 0.001
  Indeterminate 3.12 1.80–5.44  < 0.001
Pupillomotor symptom
 MDS-UPDRS I score 1.18 1.12–1.25  < 0.001
 MDS-UPDRS IV score 1.33 1.09–1.65 0.006
 Depression
  No Ref
  Yes 0.47 0.25–0.85 0.01
 Subtype
  TD Ref
  PIGD 1.86 1.08–3.19 0.03
  Indeterminate 3.35 1.79–6.23  < 0.001
Sexual function symptom
 Age of onset 1.03 1.01–1.05 0.003
Hoehn and Yahr stage
 Stage 1 Ref
 Stage 1.5 0.10 0.005–0.56 0.03
 Stage 2 0.83 0.55–1.25 0.38
 Stage 2.5 0.79 0.04–5.43 0.83
 Stage 3 1.12 0.04–0.48 0.91
 MDS-UPDRS I score 1.14 1.09–1.21  < 0.001
 Depression
  No Ref
  Yes 0.45 0.25–0.80 0.008
 LED 0.99 0.990–0.996  < 0.001
 Subtype
  Indeterminate Ref
  PIGD 0.45 0.22–0.94 0.03
  TD 0.68 0.36–1.27 0.23

Abbreviations: PD Parkinson’s disease, Ref reference, OR odds ratio, CI confidence interval, MDS-UPDRS Movement Disorder Society revision of the Unified Parkinson’s Disease Rating Scale, pRBD probable rapid eye movement sleep behavior disorder, PIGD postural instability and gait disturbance, TD tremor dominant, LED levodopa equivalent dose, PIGD postural instability and gait disturbance, TD tremor dominant.